Results tagged “Vaccine Trials” from Vaccination News

"If I had a child now, the last thing I would allow is vaccination."
-Retired Vaccine Researcher to Jon Rappoport
 
Editor's Note -- This interview was posted by Jon Rappoport in early January 2002. You will discover by reading it that the very issues we now face of FORCED vaccination of a laboratory-created vaccine to "protect" us against a laboratory-created "disease" (Swine Flu, Bird flu, etc.) was set into motion a long time ago.

The vaccine researcher quoted here flat out says that the World Homicide Organization, WHO, is driven by a DEPOPULATION agenda, and that many African leaders know full well that the explosive spread of HIV and AIDS in Africa was caused by WHO-sponsored vaccinations of the 1970s.

Early tests set the stage for health workers to administer the vaccine as an aerosol instead of an injection.

A new powdered form of BCG, the tuberculosis vaccine, mixes a mycobacterium [green] with leucine [gray] and may pave the way for more powerful, needle-free forms of the vaccine.

A new powdered form of tuberculosis (TB) vaccine may help save some of the nearly two million lives lost to the disease annually. In preliminary tests, the powdered form contained more active bacterial cells than a freeze-dried version similar to the existing vaccine. The result may pave the way for health workers to administer the vaccine as an aerosol to the lungs instead of as an injection, possibly leading to a more effective treatment.

The Wits University has launched an HIV vaccine trial site at Mkhuhlu in Mpumalanga. The launch was attended by Nozizwe Madlala-Routledge, the deputy minister of the department of health and Derek Hanekom, the deputy minister of the department of science and technology.

This trial site is the first to be established in a rural area in the country. The four other HIV vaccine sites are in urban areas including Soweto, Cape Town, Pretoria and Klerskdorp. Steve Pollman, a professor at Wits University says the HIV vaccine trial site is expected to start functioning in July. He says there will be more than one HIV vaccine to be tested. The vaccine trials are expected to last for three years.

Feb. 9, 2007 -- An AIDS vaccine that uses a genetically engineered smallpox virus to boost anti-HIV immunity looks promising in early tests on humans.

In animal tests, the vaccine did not protect monkeys against infection with an AIDS virus. But vaccinated animals remained healthy -- and suffered no immune damage from the deadly virus.

Now, nine humans have received small doses of the vaccine: about one-tenth of the full dose. The vaccine was safe. And even at this tiny dose, it stimulated the kind of immune responses that protected monkeys.

The vaccine is the brainchild of Harriet Robinson, MD, chief of microbiology and immunology at Yerkes National Primate Research Center. Robinson is chief scientific advisor to GeoVax Labs Inc. of Atlanta, spun off from Emory University's vaccine center to market the vaccine.

A study has found that men with advanced, often untreatable prostate cancer who received a therapeutic cancer vaccine went on to survive longer than those receiving a placebo.
Study findings showed the vaccine group lived up to an average of four-and-a-half months longer and had a greater than three-fold increase in survival at 36 months when compared to patients in the placebo group.

The study is published in the Journal of Clinical Oncology.

The double-blind, placebo-controlled phase III clinical trial was conducted to test the efficacy of the vaccine, called sipuleucel-T, in delaying disease progression and prolonging survival in patients with asymptomatic metastatic hormone refractory prostate cancer (HRPC).

Ugandan and American Aids researchers have begun the first ever clinical trial of a vaccine to prevent mother-to-child transmission of HIV through breast-feeding which, if successful, could prevent at least 25,000 infections in new-borns in East Africa alone.

In the first phase of the trials the researchers will be testing whether the vaccine, formally known as ALVAC-HIV, is safe for use in children, following which they will study whether it can stop the transmission of the Aids virus to a suckling baby through breastmilk. Preliminary results are expected in mid-2007.

According to the UNAids, breast-feeding by HIV-positive mothers accounts for more than a third of all infections in new-borns, translating to about 1,800 children each day around the world. In Uganda alone, at least 8,000 of the country's 22,000 infections in children each year occur as a result of breast-feeding.

A second phase of clinical tests of China's hepatitis B vaccine are being carried out on 46 chronic hepatitis B patients to test the vaccine's effectiveness, said expert Wu Yuzhang.

The patients began treatment in June and will remain under close medical observation until the tests end next March, said Wu, head of the Immunology Institute of the People's Liberation Army.

The research team headed by Wu completed the first phase of clinical tests of the vaccine in June 2003. Nine months of monitoring found no safety concerns on a group of 52 healthy volunteers.

LONDON (AFX) - Bavarian Nordic AS said it has started a Phase I and a Phase I/II clinical study in Europe with MVA-BN polytope vaccine against HIV.

The vaccine was recently released from the company's facility in Berlin for use in clinical trials.

Results from both studies are expected in the second half of 2007.

MVA-BN polytope is the second of the company's three vaccine candidates to enter clinical trials.

source

HIV/AIDS vaccine trials to prevent mother-to-child transmission through breast-feeding have started at Mulago Hospital, writes Hillary Kiirya.

The trail, the first in Africa, started on Thursday on the first-born baby out of the 50 mothers screened.

"Making breastfeeding safe is possibly the most important challenge for those involved in the prevention of mother-to-child transmission in Sub-Saharan Africa," said Prof. Francis Mmiro, the lead investigator of the study.

There was a documentary aired in Norway which raised doubts about meningococcal vaccine safety.

"To say it nice, they enlisted hundreds of thousands of small kids into a gigantic experiment,"

..project leaders knew that subjects might suffer serious complications during the trial..[but] Trial subjects were not properly informed about the possibility of serious side effects during the trial..

A Swedish teen has become the first person outside the test group to be vaccinated against cervical cancer.

The newspaper “Metro” reports that 17 year old Terese Åkerlund received the vaccination with the medicine Gardasil Monday at Stockholm’s Queen Sophia Hospital.

While the majority of news websites are spamming that there are enough flu shots for the next "flu season", at the same time there are some reports of flu shots not being available straight away. In my opinion all this is nothing else but a "battage" or a stir created by PR departements of pharmaceutical companies and related media corporations.

It will be a shame to miss something which in reality is much more important than a hype against a shot which will "save" you from 2 weeks of sneezing.

Here it is:

The first HIV vaccine trial in Jamaica has begun with 24 persons who have volunteered to be tested from an experimental vaccine. Beginning today, The Sunday Gleaner will carry a diary of persons participating in the study. Dr. Peter Figueroa, chief of epidemiology and AIDS at the Ministry of Health, said it was not possible for persons to contract HIV or develop AIDS from the experimental vaccine. "I must stress that it is not possible to get HIV infection or develop AIDS from experimental vaccines< because they are not made from live HIV, killed HIV (or) weakened HIV or infected cells," he stated

CARLSBAD, Calif., Oct. 10 (UPI) -- U.S. firm Immune Response Corp. said Tuesday it has secured a contractor for its phase 2 trial of NeuroVax, a vaccine for multiple sclerosis.

The company said it has contracted with Accelsiors CRO & Consultancy Services to oversee the study.

IRC said it would start enrolling patients in the study by the end of the year, eventually recruiting 200 subjects with relapsing-remitting MS.

---

By Efam Dovi, Accra, 10 October 2006

Hundreds of children are taking part in a malaria vaccine trial in six African countries. The U.N. says the mosquito-borne disease claims more than one-million lives globally each year, 90 percent of them in sub-Saharan Africa, and the vast majority children.

Poverty and lack of organization have frustrated Africa's efforts to control malaria's spread with low-tech means - such as spreading oil on stagnant ponds where mosquitoes breed and distributing window screens and bed nets.

Now, a vaccine program, sponsored in part by the Belgium-based pharmaceutical company GlaxoSmithKline Biologicals, is showing promising signs for many African countries.

CHONBURI, Thailand -- Inside a ramshackle Buddhist temple here on the country's southeastern coast, curious villagers gathered last fall as part of the United States' biggest gamble yet on stopping the AIDS pandemic.

The informational meeting was almost like a game show as attractive young hosts revved up the crowd, working up to the big question, boomed out over loudspeakers: Would the audience be willing to volunteer to test an experimental HIV vaccine?